Expert Talks Significance of Relatlimab/Nivolumab Approval for Metastatic Melanoma
Hussein A. Tawbi, MD, PhD, principal investigator of the phase 2/3 RELATIVITY-046 trial, highlights the importance of relatlimab/nivolumab’s recent FDA approval in melanoma.
Expert Explains Significance of LAG-3 Inhibition in Novel Immunotherapies for Melanoma
LAG-3 represents a potentially relevant immune checkpoint pathway in melanoma treatment.
Expert Explains Rationale Behind RELATIVITY-047 in Melanoma
Dr. Hussein Tawbi, MD, PhD, explains the rationale behind the RELATIVITY-047 trial in melanoma and how the LAG-3 findings could further revolutionize immunotherapy.
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
2 Clarke Drive Cranbury, NJ 08512